Related Experiment Videos
The Initiation Management Predischarge Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF)
Wendy A Gattis1, Christopher M O'Connor, Mihai Gheorghiade
1Department of Medicine, Divisions of Clinical Pharmacology and Cardiology, Duke University Medical Center, Durham, North Carolina, USA.
Insights
Initiating carvedilol before hospital discharge significantly improves beta-blocker use in heart failure patients. This strategy enhances adherence to guidelines and promotes long-term medication use for better outcomes.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Beta-blocker underutilization for heart failure (HF) persists in the US despite guideline recommendations.
- Current guidelines often delay beta-blocker initiation post-hospitalization for HF.
- Evidence-based medicine adoption in HF management requires improvement.
Purpose of the Study:
- To assess the safety and efficacy of initiating carvedilol before hospital discharge in HF patients.
- To determine if pre-discharge initiation improves 60-day beta-blocker use compared to usual care.
- To explore strategies for enhancing evidence-based pharmacotherapy in clinical practice.
Main Methods:
- The Initiation Management Predischarge Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) is a multicenter, open-label trial.
- 375 HF patients were randomized to either pre-discharge carvedilol initiation or usual care.
- The primary endpoint was the proportion of patients on any beta-blocker at 60 days post-discharge.
Main Results:
- In-hospital initiation of carvedilol was found to be safe and effective.
- This strategy significantly increased the number of patients treated with beta-blockers at 60 days.
- The study demonstrated improved adherence to guideline-recommended therapy.
Conclusions:
- Initiating beta-blocker therapy prior to hospital discharge is a viable strategy to improve long-term medication use in heart failure.
- This approach helps bridge the gap between guideline recommendations and clinical practice.
- Optimizing beta-blocker therapy can reduce morbidity and mortality in heart failure patients.
Abstract:
The utilization of b-blockers for the treatment of heart failure in the United States is inadequate despite the available data and the current guidelines that support their use. The ongoing Initiation Management Predischarge Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) study was designed to determine if initiation of beta-blockade prior to hospital discharge is safe and effective in improving the 60-day use of beta-blockers in patients with heart failure. IMPACT-HF is a community-based, multicenter, open-label trial of 375 heart failure patients randomized to carvedilol initiated before their hospital discharge or to usual care (Heart Failure Society of America guidelines that recommend waiting 2-4 weeks after hospitalization for heart failure before initiating beta-blocker therapy). The entry criteria are nonrestrictive to ensure inclusion of patients reflective of the general heart failure population. The primary endpoint of the study is the number of patients treated with any beta-blocker at 60 days. A concurrently ongoing pilot registry will enroll 550 patients, admitted with exacerbated heart failure, in three phases to collect demographic, clinical, treatment patterns, and outcome data. The trial will test the tolerability of beta-blocker initiation in the hospital setting, develop strategies to improve the use of evidence-based medicine in clinical practice, and explore the patient's course from hospital admission through discharge and up to 60 days. The trial data will determine if in-hospital initiation of beta-blocker therapy is effective at improving the long-term use of pharmacologic agents proven to reduce morbidity and mortality.